Replies to post #429697 on Anavex Life Sciences Corp (AVXL)

[Steady_T]

Eisai’s application, which was completed in early May 2022, has been granted Priority Review, with a Prescription Drug User Fee Act (PDUFA) action date of January 6, 2023.

https://investors.biogen.com/news-releases/news-release-details/us-fda-accepts-and-grants-priority-review-eisais-biologics

[sab63090]

Doc328

Actually, they followed a clear cut process, the normal way to do these things (from my impression)....at least they did follow accepted medical protocols...this has been an adventure/education in management execution with results....I've read that they won approval based on that. I have also seen numerous write ups in various publications and recently in the AARP magazine suggesting this as a breakthrough, albeit expensive to CMS (and taxpayers).

My wife even discussed it with me; I told her about the negatives I've read about, too....she said she will do nothing at this point...

I would not even consider it for myself; I have now had a lot of doubt about the new Big Pharma push for RSV, Flu, and Covid shot.. It's revenues for them and trouble for us! I am more worried for the younger generation and ethics at this time.

You provide great information and I certainly understand your reasoning.....I guess I'll give Missling more time....